SC+ has the potential to revolutionise treatment options for patients with kidney disease, and I am pleased to be joining QUANTA at this exciting time. My previous experience in scaling up production capacity, simplifying the supply chain, introducing automation and increasing quality, on both sides of the Atlantic, will enable me to hit the ground running at this critical juncture and I am excited by what QUANTA can achieve in the coming years.